Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3] [4] [8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10] Treatment should be stopped if no benefit ...
Molar mass. 145089.74 g·mol −1. Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [ 1 ][ 2 ] Donanemab was developed by Eli Lilly and Company. [ 3 ][ 4 ] The most common side effects include amyloid-related imaging abnormalities and headache.
Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. [ 10 ][ 11 ][ 8 ] It is taken by mouth. [ 10 ][ 8 ] Common side effects include headache, constipation, sleepiness, and dizziness. [ 10 ][ 11 ] Severe side effects may include blood clots, psychosis ...
September 28, 2022 at 8:45 AM. A dementia charity has hailed a “historic moment” in Alzheimer’s research as a new drug has been found to reduce memory decline among patients with early-stage ...
Cholinesterase inhibitors (ChEIs), also known as anti- cholinesterase, are chemicals that prevent the breakdown of the neurotransmitter acetylcholine or butyrylcholine. This increases the amount of the acetylcholine or butyrylcholine in the synaptic cleft that can bind to muscarinic receptors, nicotinic receptors and others.
Parkinson’s disease and Alzheimer’s disease risk are lowered in people who take a type of type 2 diabetes drug, a study from South Korea has shown. Researchers from Yonsei University College ...
Therefore, early and accurate diagnosis of dementia and staging can be essential to proper clinical care. Without the ability to reliably assess dementia across the board, the misuse of anti-dementia compounds could have negative consequences, such as patients receiving the wrong medication, or not receiving treatment in the early stages of ...
Aducanumab is a monoclonal IgG1 antibody that binds to the amyloid beta protein at amino acids 3–7, which is posited to result in slowing the progression of Alzheimer's disease. [ 5 ] The mechanism is based on the amyloid hypothesis, which posits that amyloid proteins cause Alzheimer's disease, hence removing amyloid should slow the ...